Fitch: U.S. CMBS Delinquencies Tick Up Again

NEW YORK--(BUSINESS WIRE)-- U.S. CMBS delinquencies rose in May for the second straight month, according to Fitch Ratings in its latest weekly U.S. CMBS newsletter.

Loan delinquencies increased six basis points (bps) in May to 2.98% from 2.92% a month earlier. The dollar balance of late-pays increased $173 million to $11.22 billion from $11.05 billion in April. The increase was largely driven by the addition of three loans over $50 million into the index, a large mixed-use loan and two large retail portfolio loans.

The largest new delinquency, which contributed to an 83-bps spike in the mixed-use delinquency rate, was the $150 million City Place loan (CSMC 2007-C1). The loan, secured by a 731,886 square foot (sf) mixed-use property containing retail, office and multifamily components located in West Palm Beach, FL, was first transferred to the special servicer in April 2010 and was modified into A/B notes in December 2011. The largest resolution was the Coventry Mall asset (MSC 2005-TOP17). The asset, which became REO in October 2013, was a 796,194 sf regional mall located in Pottstown, PA. The loan was transferred to special servicing two times, first in February 2011 and then again in December 2012.

Current and previous delinquency rates by property type are as follows:

--Retail: 4.56% (from 4.42% in April);

--Office: 4.15% (from 4.16%);

--Hotel: 3.47% (from 3.59%);

--Multifamily: 0.87% (from 0.90%);

--Industrial: 3.41% (from 3.34%);

--Mixed Use: 4.08% (from 3.25%);

--Other: 0.79% (from 0.72%).

Additional information is available in Fitch's weekly e-newsletter, 'U.S. CMBS Market Trends', which also contains recent rating actions and an overview of newly released CMBS research, including Fitch presales and Focus reports. The link below enables market participants to sign up to receive future issues of the E-newsletter:

'http://pages.fitchemail.fitchratings.com/CMBSMktOptin/'

Additional information is available at www.fitchratings.com.

ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS. PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK: HTTP://FITCHRATINGS.COM/UNDERSTANDINGCREDITRATINGS. IN ADDITION, RATING DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH WEBSITE.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160613005873/en/

Fitch Ratings
Mary MacNeill
Managing Director
+1-212-908-0785
Fitch Ratings, Inc.
33 Whitehall Street
New York, NY 10004
or
Melissa Che
Director
+1-212-612-7862
or
Media Relations
Sandro Scenga, +1 212-908-0278
[email protected]

Source: Fitch Ratings

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• 6 Best Crypto Presales as $1.28B in August Token Unlocks Make Launch Supply the New Retail Battleground
• Beasley Broadcast Group Announces Postponement of Reporting of Q2 2026 Financial Results and Date of Conference Call and Webcast
• Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera